IDH2 and acute myeloid leukemia: Nevertheless, we have to not forget that a good characterization of our AML patients is today more and more necessary for leading ab initio the choice of the most appropriate treatment, in the new era where target therapies, such as those against FLT3, c-KIT, IDH1 or IDH2 are a reality.